Seeking Alpha

Rosetta Genomics (ROSG +9.7%) spikes as New York grants final approval for its miRview lung...

Rosetta Genomics (ROSG +9.7%) spikes as New York grants final approval for its miRview lung assay that can accurately differentiate between the four main subtypes of lung cancer using small amounts of tumor cells. With this approval, ROSG can continue to offer miRviev in all 50 U.S. states; NY is the only state that requires an independent regulatory review process for lab-developed tests.
Comments (1)
  • jazztomato
    , contributor
    Comment (1) | Send Message
     
    You missed the real reason - what you suggest is old news. Here is today:

     

    Rosetta Genomics: Spike attributed to U.S. patent filing targeting MicroRNAs for treatment of liver cancer (4.57 +0.30)
    23 Nov 2012, 10:35 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|